Antiva Biosciences Closes $53 Million Series E Equity Financing Led By Mpm-Bioimpact Capital And Names Kristine Ball President And Ceo
Amount Raised
$53 Million
Round Type
Series E
Redwood CityBiotechnologyScience And EngineeringInvestors
Description
Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, today announced the closing of a $53 million Series E equity financing. The financing was supported by a syndicate of premier life science investors led by MPM-BioImpact Capital, and joined by the company's existing investors including Canaan Partners, Sofinnova Investments, Adjuvant Capital, GV and Lumira Ventures, among others. In conjunction with the financing, president and chief executive officer Gail Maderis is transitioning to chairman of the company's board of directors and is being succeeded as CEO by Kristine Ball. Additionally, Ms
Quick answer
Antiva Biosciences raised $53 Million in a Series E round, dated April 27, 2023. Investors: Brian Goodman, Ph.D., Florencia Segal, M.D., Ms. Ball, Lumira Ventures, GV, Adjuvant Capital, Sofinnova Investments and Canaan Partners. Antiva Biosciences is based in Redwood City, California, United States.
- How much did Antiva Biosciences raise?
- Antiva Biosciences raised $53 Million in a Series E round on April 27, 2023.
- Who invested in Antiva Biosciences?
- Brian Goodman, Ph.D., Florencia Segal, M.D., Ms. Ball, Lumira Ventures, GV, Adjuvant Capital, Sofinnova Investments and Canaan Partners are named as investors in this round.
- What does Antiva Biosciences do?
- Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection.
- Where is Antiva Biosciences based and how big is it?
- Antiva Biosciences is based in Redwood City, California, United States.
- Who are the decision-makers at Antiva Biosciences?
- Fundz holds 2 contacts at Antiva Biosciences, including the Executive Officer, Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Antiva Biosciences that raised within 45 days of this round, from Fundz verified event records.
- Upstream Bio raised $200M (Series B) on June 8, 2023.
- GenEp raised $5M (Seed) on May 17, 2023.
- Ray Therapeutics raised $14M on May 15, 2023.
- Wheeler Bio raised $31M (Series A) on April 13, 2023.
- Geneos Therapeutics raised $5M (Series A) on April 12, 2023.
- Geneos Therapeutics raised $5M (Series A) on March 31, 2023.
Who to call at Antiva Biosciences, and when
A new round usually means Antiva Biosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Antiva Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Antiva Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Antiva Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Antiva Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Antiva Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.